HOOK: hookipapharma.com Company Value to Net Income

HOOKIPA - graphic logo of issuer HOOK

HOOKIPA Pharma Inc. (HOOK) revenues are based on payments from strategic partners and the commercialization of Vaxwave therapy. Simultaneously, the company is implementing energy-efficient laboratory solutions to minimize harmful emissions. Currently, the R&D center is testing promising immune drugs for oncology. The current PE ratio stands at -0.10, which is detailed in the company's price chart.

hookipapharma.com (HOOK) Price to Earnings Ratio: for the period 07/04/2022 - 08/16/2025

Analytical breakdowns for HOOKIPA Pharma, Inc. (HOOK)

- price and consensus price forecast:
Stock Price HOOKIPA|HOOK - Consensus Target
- market capitalization information:
Market Value HOOKIPA Pharma Inc.|HOOK - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Share HOOKIPA Pharma|HOOK - Company Book Value|Market Cap to Net Assets Ratio hookipapharma.com|HOOK - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio HOOKIPA Pharma Inc.|HOOK - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital HOOKIPA|HOOK - Company Debts|Debt to Book Value Ratio HOOKIPA Pharma Inc.|HOOK - Company Long-Term Debts|Short-Term Debt HOOKIPA Pharma|Intermediate Coverage Ratio hookipapharma.com
- earnings and market multiples details:
HOOK - Company Net Income|Expected Net Profit HOOKIPA Pharma Inc.|HOOK - Price to Earnings Ratio|Projected Price to Earnings Ratio HOOKIPA|HOOK - Price/Earnings to Growth Ratio|EV/EBITDA Multiple HOOKIPA Pharma Inc.|HOOK - Operating profit EBITDA|Net earnings per share for the last four quarters HOOKIPA Pharma|HOOK - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months hookipapharma.com|HOOK - Earnings growth in current year|Earnings growth forecast for next year HOOKIPA Pharma Inc.
Comprehensive company analysis:hookipapharma.com HOOK
Signature product of HOOKIPA Pharma, Inc.

Defensive assets are selected based on the stability of their fundamental indicators. HOOKIPA Pharma Inc. (HOOK) demonstrates this standard through competent management that optimizes capital expenditure via strategic alliances. The ratio of market capitalization to net income, reflected in the company's forward P/E, measures the cost of one unit of profit. This indicator determines the degree of overpayment for future growth. The price action of the curve allows for an assessment of market expectations regarding the efficiency of biotechnological developments.

Key competitors

P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotech|Price to Earnings Ratio CLDX|P/E Multiple Aurinia Corp|Price to Earnings Ratio BioCryst (BCRX)|veratx.com - Price to Earnings Multiple|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Market Cap to Earnings|AbCellera Bio - P/E Multiple|Company Value to Net Income TRML (Tourmaline)|Precigen, Inc. (PGEN) - Price to Earnings Ratio|Market Cap to Earnings pharming.com (PHAR)|Price to Earnings Ratio Nektar Therapeutics Inc.|Market Cap to Earnings Upstream Bio, Inc. UPB|Price to Earnings Ratio Zenas Biopharma, Inc. (ZBIO)|P/E Multiple Immunome Bio (IMNM)|P/E Multiple GOSS (Gossamer Bio, Inc.)|Business Payback Period kalvista.com (KALV)|SEPN - Price to Earnings Ratio|Market Cap to Net Income PVLA|SVRA: P/E Multiple|Rigel Corp (RIGL) - P/E Multiple|Price to Earnings Ratio ANAB|ATXS: Company Value to Net Income|Price to Earnings Ratio enGene (ENGN)|RAPT: Market Cap to Net Income|P/E Multiple JBIO (Aerovate Therapeutics)|Company Value to Net Income ACRS|Kyverna Therapeutics - P/E Multiple|TLSA - P/E Multiple|Cabaletta Bio (CABA) - Price to Earnings Ratio|Ventyx Biosciences Inc. - Company Value to Net Income|Price to Earnings Ratio Theratechnologies Inc|Price to Earnings Ratio Avalo Therapeutics Inc (AVTX)|P/E Multiple ELDN|P/E Multiple agenusbio.com (AGEN)|Climb Bio - Price to Earnings Ratio|Company Value to Net Income ZURA|aTyr - P/E Multiple|Business Payback Period Adagene ADAG|ikenaoncology.com (IMA) - Price to Earnings Ratio|Price to Earnings Multiple STTK|EQ (Equillium Inc) - P/E Multiple|Price to Earnings Ratio Connect Pharma (CNTB)|Price to Earnings Ratio IMUX (Immunic, Inc.)|Business Payback Period atarabio.com|P/E Multiple IFRX (InflaRx)|Company Value to Net Income XFOR|ACET - Price to Earnings Ratio|Market Cap to Earnings Celularity Inc.|INmune Bio Corp (INMB) - Price to Earnings Ratio|Market Cap to Earnings Barinthus Biotherapeutics Corp (BRNS)|Price to Earnings Ratio Kezar Life Sciences|P/E Multiple sabbiotherapeutics.com|Price to Earnings Ratio Akari Therapeutics Plc (AKTX)|ENLV: Market Cap to Net Income|P/E Multiple QTTB (Q32 Bio)|Company Value to Net Income GOVX|Edesa Biotech, Inc. - P/E Multiple|IBIO - P/E Multiple|carismatx.com (CARM) - Price to Earnings Ratio|XTL Biopharmaceuticals Ltd - Company Value to Net Income|Price to Earnings Ratio Bolt Biotherapeutics Inc.|Price to Earnings Ratio HCW Biologics Inc (HCWB)|P/E Multiple APVO|P/E Multiple AIM ImmunoTech, Inc. (AIM)|Aditxt, Inc. - Price to Earnings Ratio|Company Value to Net Income GRI|XORTX - P/E Multiple|Business Payback Period Vyome Therapeutics HIND|Revelation Biosciences (REVB) - Price to Earnings Ratio|Price to Earnings Ratio indaptusrx.com|Price to Earnings Ratio Scinai Immunotherapeutics Ltd.|Price to Earnings Ratio CalciMedica Corp (CALI)|Price to Earnings Ratio AFMD (Affimed)|P/E Multiple allakos.com (ALLK)|Price to Earnings Ratio IGM Biosciences IGMS|ITOS: Price to Earnings Multiple|Ocean Biomedical - P/E Multiple|Market Cap to Earnings TC BioPharm (Holdings) Plc|THRD: P/E Multiple